Summary
Amyotrophic lateral sclerosis (ALS) is a devastating and fatal disease that slowly destroys the brain cells responsible for muscle movement. Despite decades of research, progress has been painfully slow. Since 1995, the Food and Drug Administration has approved only three drugs for ALS: riluzole, edaravone, and tofersen. Unfortunately, these treatments offer only modest benefits to patients, and the failure rate for new drug trials remains alarmingly high.
The road to developing effective ALS treatments is blocked by several major hurdles. Early lab models often fail to predict how a drug will actually work in humans. When drugs do make it to early human testing, the trials are frequently too small to provide clear answers. Finally, the later stages of clinical testing are so expensive that many promising ideas run out of money before they can be proven effective. Even recent federal efforts, like the ACT for ALS Act, have not fully closed the massive funding gaps required to run large clinical trials across multiple sites.
To break this cycle, researchers are calling for a complete overhaul of how ALS research is funded and organized. This includes building stronger national patient databases, using flexible trial designs that can test multiple drugs at once, and creating clever financial strategies like milestone-based partnerships between public and private groups. Because this work is a broad review of the funding ecosystem rather than a primary clinical study, it does not offer new patient data. Instead, it provides a crucial blueprint for fixing the system itself.
Why it matters.
A coordinated, sustainable approach to funding could finally transform how we treat ALS, giving real hope to patients who currently face a dire prognosis with few medical options. If the scientific community can successfully pool resources to fund late-stage trials and keep research networks alive, it could rapidly speed up the delivery of truly effective therapies to the clinic.
The impact of fixing this broken system stretches far beyond a single condition. A successful financial and collaborative model for ALS could serve as a blueprint for tackling other rare neurodegenerative and genetic disorders. By proving that smart funding partnerships and shared trial platforms work, the medical industry could unlock new treatments for countless rare diseases that are currently stalled by the exact same financial roadblocks.
The story in numbers.
- FDA-approved drugs for ALS since 1995
- 3
- Year since which current ALS therapies were approved
- 1995
Follow the evidence.
This AI-assisted summary is a starting point. Read the original reporting for its methods, scope, and limitations.